Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Apax Partner’s portfolio company Destiny in connection with its acquisition of Soluno
Mandate

Vinge advises Apax Partner’s portfolio company Destiny in connection with its acquisition of Soluno

June 21, 2021 Employment and Benefits Commercial Agreements M&A IT, Telecommunications and Outsourcing Real Estate and Construction Corporate Crime & Compliance Intellectual Property

Vinge advises Destiny (a portfolio company of Apax Partners) in connection with its acquisition of the Soluno group (“Soluno”).

Soluno is one of the leading unified communications as a service providers in Europe. The acquisition gives Destiny an instantly strong position in Sweden and also leads to globalisation for Soluno. Following the acquisition, Destiny will comprise of more than 600 employees across 6 countries and is expected to generate a turnover of SEK 1.7 billion in 2021.

Vinge’s team mainly consisted of Christina Kokko, Ulrich Ziche, Hannah Kajlinger and Carl Fredrik Wachtmeister (M&A), Lisa Hörnqvist (Commercial Agreements and GDPR), Mathilda Persson (IT), Ulf Pyk (Real Estate), Josefine Lanker (Banking and Financing), Ebba Svenburg (Employment), Tove Lövgren Frisk (Compliance), Felizia Wiker (IP) and Sara Dahlroos Sköld (VDR specialist).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026